Metabolic profiling detects field effects in nondysplastic tissue from esophageal cancer patients

Cancer Research

Volumn 70, Issue 22, 2010, Pages 9129-9136

  Yakoub, Danny ^a   Keun, Hector C ^a   Goldin, Robert ^a   Hanna, George B ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; GLUTAMIC ACID; GLYCINE; HYPOXANTHINE; INOSINE; INOSITOL; PHOSPHORYLCHOLINE; URACIL; URIDINE;

ADULT; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER TISSUE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; METABOLIC PARAMETERS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RECEIVER OPERATING CHARACTERISTIC;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CELL TRANSFORMATION, NEOPLASTIC; DIAGNOSIS, DIFFERENTIAL; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; GLUTAMIC ACID; HUMANS; INOSINE; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOME; MIDDLE AGED; MUCOUS MEMBRANE; MULTIVARIATE ANALYSIS; PHOSPHORYLCHOLINE; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 78549258540     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1566     Document Type: Article

References (41)

1. Ferlay J, et al. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. CancerBase No. 5. Lyon: IARCPress; 2004.
2. Lerut T, Nafteux P, Moons J, et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg 2004;240:962-72.
3. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002;97: 1888-95.
4. Lovat LB, Johnson K, Mackenzie GD, et al. Elastic scattering spectroscopy accurately detects high grade dysplasia and cancer in Barrett's oesophagus. Gut 2006;55:1078-83.
5. Telford JJ, Enns RA. Endoscopic missed rates of upper gastrointestinal cancers: parallels with colonoscopy. Am J Gastroenterol 2010; 105:1298-300.
6. Falk GW, Rice TW, Goldblum JR, et al. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 1999;49:170-6.
7. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953;6:963-8.
8. Slaughter DP. Multicentric origin of intraoral carcinoma. Surgery 1946;20:133-46.
9. Roesch-Ely M, Nees M, Karsai S, et al. Proteomic analysis reveals successive aberrations in protein expression from healthy mucosa to invasive head and neck cancer. Oncogene 2007;26:54-64.
10. Rosenthal AN, Ryan A, Hopster D, et al. Molecular evidence of a common clonal origin and subsequent divergent clonal evolution in vulval intraepithelial neoplasia, vulval squamous cell carcinoma and lymph node metastases. Int J Cancer 2002;99:549-54.
11. Shen L, Kondo Y, Rosner GL, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005;97: 1330-8.
12. Heaphy CM, Bisoffi M, Fordyce CA, et al. Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer 2006;119: 108-16.
13. Furlan D, Carnevali I, Marcomini B, et al. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas. Clin Cancer Res 2006;12:3329-36.
14. Hanson JA, Gillespie JW, Grover A, et al. Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst 2006; 98:255-61.
15. Wong DJ, Paulson TG, Prevo LJ, et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001;61:8284-9.
16. Dakubo GD, Jakupciak JP, Birch-Machin MA, et al. Clinical implications and utility of field cancerization. Cancer Cell Int 2007;7:2.
17. Nicholson JK, Lindon JC, Holmes E. "Metabonomics": understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999;29:1181-9.
18. Beckonert O, Coen M, Keun HC, et al. High-resolution magic-angle- spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat Protoc 2010;5:1019-32.
19. 1H magnetic resonance spectroscopic imaging study with ex vivo correlation. Eur Radiol 2009;19: 2041-8.
20. Chan EC, Koh PK, Mal M, et al. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res 2009;8:352-61.
21. 1H MR spectra. Int J Mol Med 2006;18:859-69.
22. Celda B, Monleon D, Martinez-Bisbal MC, et al. MRS as endogenous molecular imaging for brain and prostate tumors: FP6 project "eTUMOR". Adv Exp Med Biol 2006;587:285-302.
23. Sitter B, Lundgren S, Bathen TF, et al. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed 2006;19:30-40.
24. Swanson MG, Vigneron DB, Tabatabai ZL, et al. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI- targeted postsurgical prostate tissues. Magn Reson Med 2003;50:944-54.
25. Cheng LL, Burns MA, Taylor JL, et al. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res 2005;65:3030-4.
26. Calabrese C, Pisi A, Di FG, et al. Biochemical alterations from normal mucosa to gastric cancer by ex vivo magnetic resonance spectroscopy. Cancer Epidemiol Biomarkers Prev 2008;17:1386-95.
27. 1H-magnetic resonance spectroscopy of Barrett's esophageal mucosa using magic angle spinning techniques. Eur J Gastroenterol Hepatol 2004;16:1199-205.
28. 1H MAS NMR spectroscopy. J Proteome Res 2009;8: 1423-30.
29. Keun HC, Ebbels TMD, Antti H, et al. Improved analysis of multivariate data by variable stability scaling: application to NMR-based metabolic profiling. Anal Chim Acta 2003;490:265-76.
30. Glunde K, Bhujwalla ZM. Choline kinase α in cancer prognosis and treatment. Lancet Oncol 2007;8:855-7.
31. Fléjou JF, Svrcek M. Barrett's oesophagus - a pathologist's view. Histopathology 2007;50:3-14.
32. Fagundes RB, Melo CR, Pütten AC, Moreira LF, de Barros SG. p53 immunoexpression: an aid to conventional methods in the screening of precursor lesions of squamous esophageal cancer in patients at high-risk? Cancer Detect Prev 2005;29:227-32.
33. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004;64:4270-6.
34. Galipeau PC, Prevo LJ, Sanchez CA, et al. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst 1999;91:2087-95.
35. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-9.
36. Mazurek S, Eigenbrodt E. The tumor metabolome. Anticancer Res 2003;23:1149-54.
37. Prevo LJ, Sanchez CA, Galipeau PC, et al. p53-mutant clones and field effects in Barrett's esophagus. Cancer Res 1999;59:4784-7.
38. Ferlito A, Shaha AR, Rinaldo A, et al. "Skip metastases" from head and neck cancers. Acta Otolaryngol 2002;122:788-91.
39. D'Journo XB, Doddoli C, Michelet P, et al. Transthoracic esophagectomy for adenocarcinoma of the oesophagus: standard versus extended two-field mediastinal lymphadenectomy? Eur J Cardiothorac Surg 2005;27:697-704.
40. Bhattacharya A. Surgeons get real-time tissue profiling. Nature 2009, doi:10.1038/news.2009.1128.
41. 13C magnetic resonance imaging and spectroscopy. Nat Med 2007;13:1382-7.